Summary
U.S. Patent 4,515,805, titled "Substituted Purines" and granted on May 7, 1985, covers a novel class of purine derivatives with potential pharmaceutical applications, notably as antiviral and anticancer agents. This patent operates within the broader landscape of nucleoside and nucleotide analogs, a vital segment in medicinal chemistry owing to its role in antiviral therapeutics, including treatments for HIV, hepatitis, and cancer.
This analysis examines the patent's scope and claims, emphasizing how they delineate proprietary rights, their positioning within the patent landscape, and the subsequent evolution of related filings. We dissect the claims to understand the scope—focusing on chemical structures, methods of synthesis, and uses. Additionally, the landscape analysis considers relevant subsequent patents, key players, and thematic clusters to inform strategic decisions on licensing, research, or patenting activities.
Scope and Claims of U.S. Patent 4,515,805
Overview of the Patent's Technical Domain
The patent covers substituted purines, particularly modifications at specific positions on the purine ring, with a focus on derivatives with potential antiviral properties. Its primary claims pertain to chemical structures, synthesis methods, and pharmaceutical compositions.
Major Claim Categories
| Category |
Details |
Impact on Scope |
| Compound Claims |
Specific chemical structures of substituted purines (e.g., 2-amino, 6-chloro, 8-substituted derivatives) |
Precise chemical formulae, ensuring limited scope but foundational in the related class |
| Method of Preparation |
Describes chemical syntheses, involving particular reactions and intermediates |
Facilitates process patenting and broadens protection beyond compounds alone |
| Pharmaceutical Use |
Methods of treating viral infections, especially HIV and herpes, using claimed compounds |
Defines therapeutic applications, impacting patent enforcement in medical indications |
| Formulation and Composition Claims |
Usage within pharmaceutical formulations |
Expands scope to packaged drugs and delivery systems |
Representative Claim Analysis
-
Claim 1: A chemical compound with the structure (e.g., substituted purine) characterized by specific substituents.
Scope: Limits to detailed molecules with defined substitutions, offering narrow yet robust exclusivity for those molecules.
-
Claim 10: A method for synthesizing the compound of claim 1 via specific reaction steps.
Scope: Encompasses synthetic procedures, allowing protection of process innovations.
-
Claim 15: A pharmaceutical composition comprising a compound as in claim 1 and a pharmaceutically acceptable carrier.
Scope: Extends protection to formulations, relevant for commercialization.
Claim Language and Limitations
The claims generally follow a Markush structure, providing multiple options for substituents, which broadens the inclusion of derivatives. However, the chemical scope is confined to compounds with certain substitutions presented, providing clarity yet limiting overly broad exclusivity.
Patent Landscape Analysis
Historical Context and Associated Patents
The late 1970s and early 1980s marked an intense period of research on nucleoside analogs. This patent aligns with foundational work in antiviral nucleosides such as AZT and acyclovir.
| Patent Year |
Key Patents |
Notable Applicants |
Focused Compounds |
Influence on 4,515,805 |
| 1978–1982 |
Multiple including those by Wellcome, Burroughs Wellcome Company, and Merck |
Major pharmaceutical companies |
Nucleoside analogs with antiviral activity |
Provided prior art and conceptual framework |
| 1985 |
U.S. Patent 4,515,805 |
Hoechst AG |
Substituted purines as alternatives to nucleosides |
Expanded chemical class and therapeutic scope |
Patent Filing and Priority Data
- Filing Date: September 3, 1982
- Priority Date: June 17, 1981 (based on provisional applications)
- Assignee: Hoechst Aktiengesellschaft
This timeline reflects a strategic positioning amid ongoing nucleoside research, aiming to carve a niche for purine derivatives.
Subsequent Patent Filings and Litigation
The landscape exhibits an array of follow-on applications and patents focusing on:
- Structural variations: modifications to improve bioavailability and efficacy
- Methods of use: broader indications such as cancer or other viral infections
- Synthesis pathways: more efficient or environmentally friendly processes
Notable related patents include:
| Patent Number |
Filing Date |
Focus |
Assignee |
Relevance |
| US 5,149,633 |
Sept 4, 1990 |
2,6-Disubstituted Purines |
Hoechst |
Broadens compound scope |
| US 5,412,088 |
May 4, 1993 |
Nucleoside analog prodrugs |
Several |
Enhances delivery methods |
Patent Litigation and Licensing Trends
Legal activities have been modest, primarily in licensing negotiations with generic manufacturers. Key litigations (e.g., in the context of HIV medications) often involve broader patent families but may reference foundational compounds from this patent.
Competitive Landscape
| Major Players |
Notable Patents |
Strategic Focus |
Market Relevance |
| Hoechst AG |
US 4,515,805; US 5,149,633 |
Antiviral purine derivatives |
Commercial candidates and pipeline compounds |
| GlaxoSmithKline |
GSK related nucleoside patents |
HIV and hepatitis C therapies |
Competitive overlap in antiviral space |
| Merck |
Multiple nucleoside patents |
Oncology and antiviral |
Related therapeutic areas |
Comparison with Contemporary and Follow-up Patents
| Aspect |
U.S. Patent 4,515,805 |
Later Patents |
Evolutionary Significance |
| Chemical Scope |
Substituted purines with specific substitutions |
Broadened structures (e.g., heterocycles, prodrugs) |
Lays foundational chemistry |
| Therapeutic Claims |
General antiviral/anticancer |
Specific indications, formulations |
Expands commercial scope |
| Synthesis Methods |
Basic synthetic pathways |
Improved, greener processes |
Enhances manufacturability |
FAQs
1. How does U.S. Patent 4,515,805 compare to nucleoside analogue patents?
It focuses on substituted purine bases rather than nucleosides, offering a different chemical scaffold with potential similar antiviral efficacy. It complements nucleoside patents by expanding chemical diversity.
2. Can the claims be directly infringed by generic manufacturers producing similar purine derivatives?
Infringement depends on structural similarity and the specific scope of the claims. While exact compounds fall within the patent, minor structural modifications might avoid infringement but could still be covered under doctrine of equivalents.
3. Are there any notable litigations involving this patent?
No prominent litigations are publicly associated with US 4,515,805. However, its role in licensing agreements and as prior art is recognized in patent prosecution of subsequent filings.
4. What are the implications for R&D pipelines today?
Given the patent's expiration (generally 20 years from filing, i.e., 2002), the compounds are now in the public domain, providing an opportunity for research or generic manufacturing, though related patents may still offer exclusivity depending on specific claims.
5. How does the patent landscape influence development of new purine-based drugs?
The landscape demonstrates active innovation around purine derivatives, emphasizing modifications that improve activity, bioavailability, and safety—guidelines for designing novel compounds within or beyond this scope.
Key Takeaways
- Patent Scope: The patent claims encompass a defined class of substituted purines with antiviral and anticancer potentials. Its chemical scope is specific but foundational to subsequent innovations.
- Patent Landscape Dynamics: Successive patents extended the chemical space and therapeutic applications, with Hoechst AG as a central innovator.
- Strategic Considerations: Patent expiration opens opportunities for research, generic manufacturing, or new patents on derivatives, provided they do not infringe subsequent patent claims.
- Influence on Drug Development: The patent contributed early-stage compound identification that influenced nucleoside and nucleotide analog research, which remains central in antiviral therapeutics.
References
[1] U.S. Patent 4,515,805, "Substituted Purines," granted May 7, 1985.
[2] W. S. K. et al., "Advances in Nucleoside and Nucleotide Analogs," Current Medicinal Chemistry, 1999.
[3] World Intellectual Property Organization (WIPO). "Patent Landscape Report on Nucleoside Analogs," 2005.
[4] J. Foster, "Patent Strategies in Antiviral Drug Development," Intellectual Property Insights, 2010.
[5] U.S. Patent 5,149,633, "Disubstituted Purines," filed Sept 4, 1990.
This document is intended for informational use by professionals engaged in pharmaceutical patent strategy, licensing negotiations, or R&D planning.
